title: [Granulocytapheresis in inflammatory bowel disease. Efficacy of an induction plus maintenance sessions protocol at 32 weeks].
abstract: BACKGROUND
  Granulocytapheresis (GCAP) eliminates activated granulocytes-monocytes from peripheral blood, thus modifying the circulating pool of leukocytes and reducing intestinal inflammation.
  
  
  OBJECTIVE
  To evaluate the efficacy of GCAP in inflammatory bowel disease (IBD) using an induction and maintenance protocol.
  
  
  METHODS
  A retrospective study including patients with active corticosteroid-dependent or refractory IBD. Induction included 5 sessions in ulcerative colitis (UC) and 7 sessions in Crohn's disease (CD); one monthly session was used thereafter until week 32. Clinical activity indices and use of corticosteroids were monitored.
  
  
  RESULTS
  Eighteen patients were included (10 with UC, 8 with CD), 10 of them dependent on and 8 refractory to corticosteroids. Fourteen of them were refractory and a further 4 were intolerant to immunosuppressants (IS). Induction was not completed in 2 UC (severe relapses) and 1 CD (side-effects) patients. One UC and 3 CD patients withdrew during maintenance. Among patients who completed induction, response or remission was achieved in 87.5% of UC cases (2 and 5 patients) and 71.4% of CD cases (1 and 4 patients), respectively. At week 32 response-remission rates reached 75% in CU (3 and 3 patients) and 42.8% in CD (1 and 2 patients) cases, respectively. Corticosteroid withdrawal was possible in 14.2% of CD and in 62.5% of UC patients (25% in remission and 37.5% with response). There were two major side effects (thrombophlebitis and syncope). No colectomies were performed for UC patients who completed GCAP induction after a mean follow-up of 97.6 weeks (range: 72-128).
  
  
  CONCLUSIONS
  both UC and CD respond well to GCAP induction. At 32 weeks UC patients maintain similar response-remission rates (87.5 vs. 75%), whereas almost one-third of CD patients lose response. Granolocytapheresis is an alternative, steroid-sparing treatment modality to induce and maintain remission in UC, while good patient selection and a maintenance protocol not well defined yet are needed for CD.
authors.affiliation: Unidad de Aparato Digestivo, Hospital Costa del Sol, Carretera Nacional 340, Marbella, Málaga. pacof@hcs.es
authors.forename: F J
authors.initials: FJ
authors.lastname: Fernández Pérez
authors.forename: F
authors.initials: F
authors.lastname: Rodríguez
authors.forename: C
authors.initials: C
authors.lastname: de Sola
authors.forename: N
authors.initials: N
authors.lastname: Fernández Moreno
authors.forename: F
authors.initials: F
authors.lastname: Vera
authors.forename: R
authors.initials: R
authors.lastname: Rivera
authors.forename: A
authors.initials: A
authors.lastname: Sánchez Cantos
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002985:Clinical Protocols; D005260:Female; D006098:Granulocytes; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000628:therapy*; D007937:Leukapheresis / Q000379:methods; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013997:Time Factors